EP3638226A4 - Anti-obesity potential of garcinol - Google Patents

Anti-obesity potential of garcinol Download PDF

Info

Publication number
EP3638226A4
EP3638226A4 EP18817304.1A EP18817304A EP3638226A4 EP 3638226 A4 EP3638226 A4 EP 3638226A4 EP 18817304 A EP18817304 A EP 18817304A EP 3638226 A4 EP3638226 A4 EP 3638226A4
Authority
EP
European Patent Office
Prior art keywords
garcinol
obesity potential
obesity
potential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18817304.1A
Other languages
German (de)
French (fr)
Other versions
EP3638226A1 (en
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Lakshmi MUNDKUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Sabinsa Group Ltd
Original Assignee
Sami Chemicals and Extracts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Chemicals and Extracts Ltd filed Critical Sami Chemicals and Extracts Ltd
Publication of EP3638226A1 publication Critical patent/EP3638226A1/en
Publication of EP3638226A4 publication Critical patent/EP3638226A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18817304.1A 2017-06-15 2018-06-13 Anti-obesity potential of garcinol Pending EP3638226A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519949P 2017-06-15 2017-06-15
US201762523611P 2017-06-22 2017-06-22
PCT/US2018/037242 WO2018231923A1 (en) 2017-06-15 2018-06-13 Anti-obesity potential of garcinol

Publications (2)

Publication Number Publication Date
EP3638226A1 EP3638226A1 (en) 2020-04-22
EP3638226A4 true EP3638226A4 (en) 2021-04-07

Family

ID=64659462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18817304.1A Pending EP3638226A4 (en) 2017-06-15 2018-06-13 Anti-obesity potential of garcinol

Country Status (8)

Country Link
EP (1) EP3638226A4 (en)
JP (3) JP2020523373A (en)
KR (1) KR102289324B1 (en)
AU (1) AU2018284354A1 (en)
BR (1) BR112019026824A2 (en)
CA (1) CA3066446A1 (en)
MX (1) MX2019014841A (en)
WO (1) WO2018231923A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102136335B1 (en) * 2020-03-24 2020-07-22 (주)메디톡스 Microorganism capable of improving liver function or inhibiting fat accumulation and use thereof
KR102363098B1 (en) * 2020-06-19 2022-02-16 한국식품연구원 Predicting or Diagnosing Composition for Risk of Renal Diseases Using Human Intestinal Microbiome, Diagnosing Kit, Method For Providing Information, And Screening Method For Drugs For Preventing Or Treating Renal Diseases Using The Same
KR102191487B1 (en) * 2020-06-19 2020-12-15 (주)메디톡스 Microorganism capable of improving liver function or inhibiting fat accumulation and use thereof
KR102363094B1 (en) * 2020-06-19 2022-02-16 한국식품연구원 Predicting or Diagnosing Composition for Risk of Liver Diseases Using Human Intestinal Microbiome, Diagnosing Kit, Method For Providing Information, And Screening Method For Drugs For Preventing Or Treating Liver Diseases Using The Same
KR102363088B1 (en) * 2020-06-19 2022-02-16 한국식품연구원 Predicting or Diagnosing Composition for Risk of Diabetic Disease Using Human Intestinal Microbiome, Diagnosing Kit, Method For Providing Information, And Screening Method For Drugs For Preventing Or Treating Diabetes Using The Same
KR102363092B1 (en) * 2020-06-19 2022-02-16 한국식품연구원 Predicting or Diagnosing Composition for Risk of Obesity Using Human Intestinal Microbiome, Diagnosing Kit, Method For Providing Information, And Screening Method For Drugs For Preventing Or Treating Obesity Using The Same
KR102331485B1 (en) 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 Blautia wexlerae strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof
CN114605242A (en) * 2022-04-11 2022-06-10 澳门大学 Preparation method of phloroglucinol compound, medicine, health-care product and food
CN114847475B (en) * 2022-07-05 2022-11-29 广东金骏康生物技术有限公司 Application of fermented sophora japonica rice flour for promoting growth of AKK (alkyl ketene dimer) bacteria
CN115637242B (en) * 2022-10-20 2024-09-27 中南大学 Microorganism composite microbial inoculum, preparation method thereof and red mud in-situ alkaloid removal method
CN116903760B (en) * 2023-05-25 2024-09-13 浙江大学 Auricularia auricula polysaccharide, preparation method thereof and application thereof in inhibiting obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000044468A (en) * 1998-07-29 2000-02-15 Kikkoman Corp Lipase inhibitor and antiobestic medicine or hyperlipidemia inhibitor
US20130281544A1 (en) 2010-12-30 2013-10-24 Muhammed Majeed Hepatoprotectant activity of garcinol
US8329743B2 (en) * 2011-01-10 2012-12-11 Sami Labs Limited Compositions and its use in treating obesity or inducing weight loss
AU2013318513A1 (en) * 2012-09-20 2015-04-09 Prothera Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
WO2015049553A1 (en) * 2013-10-03 2015-04-09 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy
US10300085B2 (en) * 2014-03-24 2019-05-28 Daicel Corporation Nutritional composition
CA2934156A1 (en) * 2015-11-10 2017-05-10 Muhammed Majeed Use of forskolin in the treatment of obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIN-LIN HSU ET AL: "Inhibitory effects of garcinol and pterostilbene on cell proliferation and adipogenesis in 3T3-L1 cells", FOOD & FUNCTION, vol. 3, no. 1, 18 November 2011 (2011-11-18), GB, pages 49 - 57, XP055234362, ISSN: 2042-6496, DOI: 10.1039/C1FO10209E *
HEO JAEYOUNG ET AL: "Gut microbiota Modulated by Probiotics and Garcinia cambogia Extract Correlate with Weight Gain and Adipocyte Sizes in High Fat-Fed Mice", SCIENTIFIC REPORTS, vol. 6, no. 1, 23 September 2016 (2016-09-23), XP055776502, Retrieved from the Internet <URL:http://www.nature.com/articles/srep33566> DOI: 10.1038/srep33566 *
WEI-LUN HUNG ET AL: "Protective effects of garcinol on dimethylnitrosamine-induced liver fibrosis in rats", FOOD & FUNCTION, vol. 5, no. 11, 1 January 2014 (2014-01-01), GB, pages 2883 - 2891, XP055755272, ISSN: 2042-6496, DOI: 10.1039/C4FO00342J *

Also Published As

Publication number Publication date
CA3066446A1 (en) 2018-12-20
WO2018231923A1 (en) 2018-12-20
EP3638226A1 (en) 2020-04-22
KR20200012978A (en) 2020-02-05
AU2018284354A1 (en) 2020-01-16
JP2021185156A (en) 2021-12-09
KR102289324B1 (en) 2021-08-12
JP2022097521A (en) 2022-06-30
BR112019026824A2 (en) 2020-06-30
MX2019014841A (en) 2020-02-17
JP2020523373A (en) 2020-08-06

Similar Documents

Publication Publication Date Title
EP3638226A4 (en) Anti-obesity potential of garcinol
EP3623957A4 (en) Generation of point of interest copy
EP3360534A4 (en) Sprayable sunscreen cosmetic
EP3479817A4 (en) Cosmetic
EP3353995A4 (en) Internet of things device hierarchies
EP3638808A4 (en) Detection of targeted sequence regions
EP3500286A4 (en) N-carboxyanhydride-based-scale synthesis of elamipretide
EP3603615A4 (en) Cosmetic
EP3607327A4 (en) Point of care test cartridge
EP3673894A4 (en) Cosmetic
EP3403642A4 (en) Cosmetic
EP3310794A4 (en) Synthesis and application of microbubble-forming compounds
EP3573650A4 (en) Diagnosis of scleroderma
EP3400516A4 (en) Contextual based application navigation
EP3456311A4 (en) Cosmetic
EP3468578A4 (en) Uses of il-41
EP3473237A4 (en) Lip cosmetic
EP3320901A4 (en) Application of dimethylamino micheliolide
EP3666253A4 (en) Cosmetic
EP3636249A4 (en) Cosmetic
EP3721889A4 (en) Use of butyribacter intestini
EP3520789A4 (en) New use of amlexanox
EP3482750A4 (en) Novel use of sesquiterpene derivative
EP3703702A4 (en) MODULATORS OF ENaC EXPRESSION
EP3714863A4 (en) Cosmetic

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031352000

Ipc: A61K0031122000

A4 Supplementary search report drawn up and despatched

Effective date: 20210304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/06 20060101ALI20210226BHEP

Ipc: A61P 1/00 20060101ALI20210226BHEP

Ipc: A61P 3/04 20060101ALI20210226BHEP

Ipc: A61K 31/122 20060101AFI20210226BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SAMI-SABINSA GROUP LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230509